Skip to main content

Table 2 The results of non-liner relationship between BMI and breast cancer risk

From: Body mass index had different effects on premenopausal and postmenopausal breast cancer risks: a dose-response meta-analysis with 3,318,796 subjects from 31 cohort studies

 

21.5 kg/m2

22.5 kg/m2

23.5 kg/m2

25.0 kg/m2

26.5 kg/m2

30.0 kg/m2

Post

1(Reference)

1.03(1.02–1.05)

1.07(1.04–1.10)

1.12(1.08–1.17)

1.17(1.11–1.23)

1.26(1.18–1.35)

Post-America

1(Reference)

1.03(1.02–1.05)

1.07(1.03–1.10)

1.11(1.06–1.17)

1.16(1.09–1.24)

1.26(1.15–1.38)

Post-Europe

1(Reference)

1.02(1.00–1.04)

1.04(1.01–1.09)

1.08(1.02–1.15)

1.12(1.03–1.21)

1.19(1.06–1.33)

Post-Asia

1(Reference)

1.10(1.07–1.13)

1.19(1.13–1.25)

1.32(1.24–1.41)

1.42(1.31–1.54)

1.60(1.37–1.87)

Post-HRTa non user

1(Reference)

1.04(1.02–1.07)

1.09(1.04–1.14)

1.16(1.08–1.25)

1.23(1.12–1.35)

1.37(1.20–1.57)

Post-ER + b

1(Reference)

1.03(1.01–1.04)

1.06(1.03–1.09)

1.10(1.05–1.15)

1.14(1.08–1.22)

1.23(1.15–1.32)

Pre-Europe

1(Reference)

0.98(0.96–1.00)

0.95(0.92–0.99)

0.91(0.86–0.96)

0.87(0.81–0.93)

0.76(0.67–0.86)

Pre-Asia

1(Reference)

1.00(0.97–1.04)

1.02(0.96–1.08)

1.07(0.99–1.16)

1.16(1.05–1.27)

1.48(1.20–1.83)

  1. The dose 21.5 kg/m2 is the reference group
  2. a indicates hormone replacement therapy, b indicates estrogen receptor positive status